---
ticker: "AMGN"
company_name: "Amgen Inc."
sector: "healthcare-pharma"
asset_class: "equity"
analysis_date: "2026-03-24"
analyst: "inv-AI Valuation Framework (Claude Opus 4.6)"
rating: "FAIRLY_PRICED_MID"
rating_display: "Fairly Priced (Mid)"
conviction_level: 1
confidence_score: 6.2
confidence_level: "MEDIUM"
current_price: 348.43
fair_value:
  bear: 270
  base: 344
  bull: 435
fair_value_12m:
  low: 292
  mid: 344
  high: 396
upside_to_mid: -1.3
methods:
  - name: "SOTP/Pipeline NPV"
    weight: 35
    fair_value: 330
  - name: "DCF"
    weight: 30
    fair_value: 366
  - name: "P/E Comparable"
    weight: 20
    fair_value: 346
  - name: "EV/EBITDA"
    weight: 15
    fair_value: 328
risk_reward:
  near_term_ratio: "0.63:1"
  near_term_verdict: "Unfavorable"
  long_term_ratio: "1.48:1"
  long_term_verdict: "Neutral"
cross_model_review:
  status: "PENDING"
  iterations: 0
  reviewer: "GPT-5.4"
  review_date: "2026-03-24"
shares_outstanding: 538.5
market_cap: 187.7
report_html: "/reports/AMGN.html"
---

AMGN Valuation Analysis - 2026-03-24 | inv-AI


# Amgen Inc. AMGN


Healthcare — Pharmaceuticals / Large-Cap Biotech | Patent Cliff Transition + GLP-1 Optionality + Iran War Macro Adjustment | Mega Cap Analysis Date: March 24, 2026 | Status: Pending Review (GPT-5.4) | Analyst: inv-AI (Claude Opus 4.6) | Update from: 2026-02-15


* FAIRLY PRICED (MID) — Confidence: MEDIUM (6.2/10)


| Stock Price             | $348.43                                                     |
|-------------------------|-------------------------------------------------------------|
| Weighted Fair Value     | $344 -1.3%                                                  |
| Fair Value Band (+/-15%)| $292 – $396                                                 |
| Bull / Base / Bear      | $435 / $344 / $270                                          |
| Near-Term Prob-Weighted | $338 (0.20x$420 + 0.50x$355 + 0.20x$275 + 0.10x$210)      |
| Street Consensus PT     | $350 0% (29 analysts: 4SB/7B/17H/1S)                       |
| Risk/Reward Ratio       | 0.63:1 (Unfavorable)                                        |


Thesis: Amgen's transition intensifies under new macro headwinds. The stock has fallen 5.6% since our Feb 15 initiation ($369 to $348), moving closer to fair value. The core thesis is unchanged — growth portfolio vs. patent cliff — but three new vectors require recalibration: (1) Iran war (Feb 28) creates supply chain cost inflation and macro uncertainty, partially offset by healthcare's defensive positioning; (2) FOMC's hawkish hold at 3.50-3.75% with only 1 cut projected for 2026 pressures Amgen's $54.6B debt refinancing costs; (3) MariTide MARITIME-1/2 enrollment complete (~5,000 patients) de-risks the timeline to early 2027 readout, incrementally positive. Meanwhile, Prolia/XGEVA biosimilar erosion is accelerating: CVS dropped Prolia from formularies effective April 2026, and analysts project -28%/-39% declines in 2026.


Action: HOLD at current levels. Near-term R/R improved to 0.63:1 (from 0.48:1) due to price decline, but remains unfavorable. Accumulate below $292 (lower band). The stock is now essentially at fair value — the investment case remains a "2027 story."


At $348, Amgen trades at 15.6x forward non-GAAP EPS ($22.30 midpoint) — a meaningful de-rating from 16.5x in February. The price decline has absorbed some of the overvaluation we identified, but the fundamental tug-of-war between the growth portfolio ($12.4B, +37% weighted) and the patent cliff ($9.9B, -12%) is entering its most critical phase. The Iran war adds a macro overlay: healthcare is relatively defensive (Amgen has zero Middle East revenue exposure), but oil-driven supply chain cost inflation (+$50-100M annualized for biologics cold chain logistics) and a hawkish Fed that refuses to cut rates create refinancing headwinds on $54.6B of debt. The most significant positive development since our last report is MARITIME-1/2 enrollment completion — ~5,000 patients enrolled quickly, suggesting strong investigator interest and de-risking the early 2027 readout timeline. We adjust WACC +20bps (to 8.2%) for macro risk, compress EV/EBITDA multiples modestly (12.5x to 12.0x), and mark MariTide PoS up to 55% (from 50%) on enrollment completion. Our weighted fair value moves from $352 to $344, and with the stock now at $348 (vs. $369 prior), the gap narrows from -4.6% to -1.3%. Rating unchanged: FAIRLY PRICED (MID). HOLD; accumulate below $292.


Table of Contents 1. Key Metrics & Revenue Mix 2. Investment Thesis 3. Valuation Methods 4. DCF Deep Dive 5. Scenario Analysis & Risk/Reward 6. Research Agent Findings 7. Patent Cliff & Pipeline Deep Dive 8. Catalysts 9. Key Risks 10. Macro Overlay: Iran War & FOMC 11. Contrarian Checklist 12. Position Recommendation 13. Sources & Disclaimer


## 1. Key Metrics & Revenue Mix


Current Price


52wk: $261 – $385


Weighted Fair Value


Band: $292 – $396


* Fairly Priced (Mid)


MEDIUM confidence (6.2/10)


538.5M diluted shares


FY2025 Revenue


+10% YoY (13% vol, -3% NSP)


FY2025 EPS (Non-GAAP)


GAAP $14.23 (Horizon amort.)


Forward P/E


vs Pharma median ~15x


D/E 7.57x (99th pctile)


Free Cash Flow


FCF yield ~4.6% (at $348)


Dividend Yield


$10.08/yr, 16 consecutive increases


| Metric                 | FY2022A | FY2023A | FY2024A | FY2025A     | FY2026E          |
|------------------------|---------|---------|---------|-------------|------------------|
| Revenue                | $26.3B  | $28.2B  | $33.4B  | $36.8B      | $37.0-38.4B      |
| Revenue Growth         | —       | +7%     | +18%    | +10%        | +1% to +4%       |
| EPS (GAAP)             | —       | —       | —       | $14.23      | ~$15             |
| EPS (Non-GAAP Adj.)    | $17.69  | $18.65  | $19.52  | $21.84      | $21.60-23.00     |
| Non-GAAP Op. Margin    | —       | —       | —       | 46%         | 45-46%           |
| Free Cash Flow         | —       | —       | $10.4B  | $8.1B       | ~$8.5-9.0B       |
| Products >$1B          | —       | —       | 12      | 14 (record) | —                |
| Total Debt             | —       | $61B    | $60B    | $54.6B      | ~$49B            |
| P/E (Forward Non-GAAP) |         |         |         |             | 15.6x (at $348)  |
| EV/EBITDA              |         |         |         |             | ~12.6x           |
| Dividend Yield         |         |         |         |             | 2.9% (at $348)   |

Source: Amgen SEC filings (10-K/10-Q), Q4 2025 Earnings Release, FY2026 guidance (Feb 2026). GAAP EPS depressed by Horizon intangible amortization, stock comp, and $1.2B Otezla impairment. FY2026E uses management guidance range.


### Revenue Mix (FY2025 ~$36.8B)


Prolia/XGEVA $6.3B


Rep/EVE $5.1B


Rare Dis $4.1B


Enb/Ote $3.6B


Tez/Tav $2.1B


Biosim $3.0B


Other $10.2B


Growth portfolio (green/purple/blue bars) totals ~$12.3B and growing 35%+ weighted. Declining portfolio (red bars) totals ~$9.9B and shrinking 15%+ annually. The race between growth and erosion defines the investment thesis for 2026-2028.


Key context: Amgen is simultaneously navigating three major headwinds: (1) Prolia/XGEVA biosimilar cliff — 7 approved biosimilar pairs, CVS dropped Prolia from formularies effective April 1, 2026, with XGEVA excluded and replaced by Osenvelt, management guides "accelerated erosion" with analysts projecting -28%/-39% declines; (2) Enbrel IRA collapse — negotiated price -67% effective Jan 2026, FY2025 already -33% YoY; and (3) $54.6B in Horizon acquisition debt at 7.57x D/E (99th percentile for pharma), consuming $2.8B/yr in interest, now facing higher-for-longer refinancing costs after the March 18 FOMC hawkish hold. Meanwhile, growth products added $2-3B incrementally in FY2025, 14 products exceeded $1B (record), and FCF of $8.1B enabled $6B in debt retirement.


## 2. Investment Thesis


### The Bull Thesis


Amgen's growth portfolio is delivering at scale: Repatha ($3.0B, +36%) is expanding beyond secondary prevention with VESALIUS-CV primary prevention data (+25% MACE reduction), EVENITY ($2.1B, +34%) commands 60%+ bone builder market share, BLINCYTO ($1.5B, +48%) is winning first-line ALL adoption, and IMDELLTRA ($627M first full year) received full FDA approval with a 40% death risk reduction in SCLC. Tezspire (+52%, CRSwNP expansion) and UPLIZNA (+73%) add further momentum. The Horizon rare disease portfolio ($4.1B) is scaling nicely.

The MariTide story has strengthened since February: MARITIME-1 and MARITIME-2 enrollment is complete with ~5,000 patients enrolled quickly, de-risking the early 2027 readout timeline. The NEJM publication of Phase 2 data (up to 20% weight loss, HbA1c -2.2%) provides peer-reviewed validation. Six additional MARITIME studies — cardiovascular outcomes, heart failure, and obstructive sleep apnea — are actively enrolling, broadening the potential label. Amgen's $2.6B 2026 capex plan is partly dedicated to MariTide manufacturing readiness, signaling management confidence.

The biosimilar franchise ($3.0B, +37%) creates additional optionality with pembrolizumab biosimilar in development. Healthcare's defensive positioning during the Iran war provides relative outperformance vs. cyclical sectors. At 15.6x forward EPS, the stock is cheaper than February — bull case targets $460-540 on 17-18x FY2028 EPS of $27-30.


### The Bear Thesis


The erosion math has worsened since February. CVS Caremark officially dropped Prolia from formularies and excluded XGEVA effective April 1, 2026, replacing both with Samsung Bioepis (Ospomyv) and Celltrion (Stoboclo/Osenvelt) biosimilars. Analyst projections now call for Prolia -28% and XGEVA -39% in 2026 alone. Enbrel ($2.2B, -33% FY2025) faces IRA negotiated pricing of -67%, and Otezla ($1.4B) is selected for IRA Round 2. That is $9.9B (27% of revenue) in active decline, with the erosion pace accelerating.

The macro overlay is net negative: the Iran war has pushed Brent crude above $100/barrel, increasing biologics cold chain logistics costs by an estimated $50-100M annually. The March 18 FOMC hawkish hold (3.50-3.75%, only 1 cut projected for 2026) pressures Amgen's $54.6B debt stack — the company needs to refinance ~$8-10B in 2026-2027, and higher-for-longer rates mean higher coupon costs than anticipated.

MariTide Phase 2 ITT analysis showed 16% weight loss (vs. 20% completers), with vomiting rates of 43-92%. Oral GLP-1 competition is intensifying: Novo's oral Wegovy approved Dec 2025, Lilly's oral tirzepatide advancing. MariTide would enter 3-4 years behind incumbents in a market that may favor daily pills over monthly injections. Leerink cut Q1 2026 revenue estimates 4.4% to $8.7B on inventory drawdown, and management expects lower mid-single-digit YoY revenue decline in Q1 — signaling the transition pain is front-loaded.


### Our View


The fundamental picture is unchanged: Amgen is a tug-of-war between exceptional growth and exceptionally painful erosion. What has changed is the price ($348 vs. $369) and three new vectors:

**Iran war (net modest negative):** Healthcare is defensive and Amgen has zero direct Middle East exposure. However, oil-driven supply chain inflation and macro uncertainty warrant WACC +15-20bps. The defensive positioning partially offsets — Amgen has outperformed the S&P 500 since the war began on Feb 28.

**FOMC hawkish hold (net negative):** Higher-for-longer rates directly impact Amgen's $54.6B debt. Each 25bps increase in refinancing costs on the ~$8-10B maturing in 2026-2027 adds ~$20-25M to annual interest expense. More importantly, it compresses the multiple the market assigns to levered pharma.

**MariTide enrollment complete (net positive):** MARITIME-1/2 enrollment completion with ~5,000 patients is incrementally positive. It de-risks the timeline (early 2027 readout now highly likely), demonstrates strong investigator/patient demand, and allows us to mark PoS up modestly (50% to 55%). This is the most material new development.

Our four valuation methods now produce: DCF ($366), P/E Comps ($346), EV/EBITDA ($328), SOTP/Pipeline NPV ($330). The weighted blend of $344 implies -1.3% downside from $348. The gap has narrowed substantially (from -4.6%) primarily because the stock price fell 5.6%. Near-term R/R improved to 0.63:1 (from 0.48:1) but remains unfavorable. We maintain FAIRLY PRICED (MID) with a HOLD recommendation. Accumulate below $292.


## 3. Valuation Methods


| Method                | Weight | Bear | Base | Bull | Notes                                                            |
|-----------------------|--------|------|------|------|------------------------------------------------------------------|
| 35% SOTP/Pipeline NPV | 35%    | $255 | $330 | $415 | Seg EV/Rev + pipeline rNPV $25B (MariTide PoS 55%) + platform   |
| 30% DCF               | 30%    | $282 | $366 | $505 | WACC 8.2% (+20bps Iran/FOMC), TG 2.0%, 5yr projection           |
| 20% P/E Comps         | 20%    | $281 | $346 | $401 | 15.5x FY26E non-GAAP EPS $22.30                                 |
| 15% EV/EBITDA         | 15%    | $248 | $328 | $408 | 12.0x FY26E adj. EBITDA ~$18.5B (-0.5x macro compression)       |
| Weighted Fair Value   | 100%   | $270 | $344 | $435 | Current: $348 (-1.3% to mid)                                     |


Why $344 Fair Value (vs. $352 prior)? Three adjustments: (1) WACC increased 20bps to 8.2% reflecting Iran war supply chain risk and FOMC hawkish refinancing pressure — this reduces DCF from $380 to $366; (2) EV/EBITDA compressed 0.5x from 12.5x to 12.0x reflecting macro uncertainty and higher rates — reducing from $345 to $328; (3) SOTP adjusted: Prolia/XGEVA segment reduced (CVS exclusion now confirmed) partially offset by MariTide rNPV increase (PoS 50% to 55% on enrollment completion) — net from $333 to $330. P/E unchanged at $346. Weighted: 0.30 x $366 + 0.20 x $346 + 0.15 x $328 + 0.35 x $330 = $109.80 + $69.20 + $49.20 + $115.50 = $343.70, rounded to $344.


Change from prior: FV decreased $8 (from $352 to $344, -2.3%). But the stock fell $21 (from $369 to $348, -5.6%). Net effect: stock moved from -4.6% overvalued to -1.3% overvalued. The market has done most of the adjustment work for us.


## 4. DCF Deep Dive


Step 1: WACC Calculation (Updated)


Risk-Free Rate: 4.35% (10Y UST, Mar 2026 post-FOMC, +10bps from Feb)


Beta (raw 5Y): 0.47 -> Blume adjusted: 0.67 x 0.47 + 0.33 x 1.0 = 0.645


Forward adjustment: +0.055 for systematic risk (IRA policy shift, biosimilar interchangeability) -> 0.70


Equity Risk Premium: 5.5%


Cost of Equity = 4.35% + 0.70 x 5.5% = 8.20%


Cost of Debt (pre-tax): $2.755B / $54.6B = 5.05% | After-tax: 5.05% x (1 - 0.14) = 4.34%


Capital Structure (market weights): 77.5% equity ($188B mkt cap at $348) / 22.5% debt ($54.6B gross at book)


WACC = 0.775 x 8.20% + 0.225 x 4.34% = 7.33% + 0.87% company-specific premium = 8.2%


+87bp premium for unsystematic risks NOT in beta: (1) highest book D/E in pharma at 7.57x creating refinancing risk heightened by FOMC hawkish stance, (2) triple simultaneous LOE exceeding typical pharma pattern, (3) MariTide Phase 3 binary risk, (4) Iran war supply chain inflation for biologics cold chain. Premium increased from 71bps to 87bps vs. February, reflecting new macro headwinds.


Step 2: Revenue Projections ($B) — Updated


FY2026E: $37.7B (+2.6% YoY, guidance midpoint) | FY2027E: $38.2B (+1.3% YoY) — trough year (revised down from $38.5B on faster Prolia erosion)


FY2028E: $40.5B (+6% YoY) | FY2029E: $43.5B (+7% YoY)


FY2030E: $47.0B (+8% YoY) — MariTide ramp if approved. 5-yr CAGR: 4.5%


FY2027 trough slightly deeper than prior: Prolia/XGEVA erosion now expected -28%/-39% in 2026 (CVS formulary exclusion confirmed), continuing into 2027. Recovery from 2028 as legacy erosion diminishes and MariTide/IMDELLTRA scale.


Step 3: Unlevered FCF Projections ($B)


FY2026E: $12.95B | FY2027E: $12.80B | FY2028E: $14.00B


FY2029E: $15.30B | FY2030E: $17.00B


UFCF = Revenue x Adj Op Margin x (1 - Tax 14-16%) + Tangible D&A (~$1.5B) - Capex (~$2.6B) - NWC change (~$0.5B). Interest excluded (WACC-based). Tax rate increased to 16-17.5% range per updated 2026 guidance (from 14% effective).


Step 4: Terminal Value


Terminal FCF = $17.00B x (1 + 2.0%) = $17.34B


Terminal Value = $17.34B / (8.2% - 2.0%) = $279.7B


TV as % of EV = 77% (appropriate for diversified pharma with long-dated pipeline optionality)


Step 5: Enterprise to Equity Bridge


PV of FCFs: $55.3B | PV of Terminal Value: $190.1B


Enterprise Value: $245.4B


Less Net Debt: $45.5B (Debt $54.6B - Cash $9.1B)


Equity Value: $199.9B / 538.5M shares = $371/share (raw DCF)


Qualitative adjustment: -1.5% for Iran supply chain risk not captured in WACC


Adjusted DCF: $366/share


### DCF Sensitivity Table ($/share)


| WACC \ TG   | 1.5% | 2.0% | 2.5% |
|-------------|------|------|------|
| 7.2%        | $420 | $462 | $513 |
| 8.2% (base) | $340 | $366 | $399 |
| 9.2%        | $282 | $301 | $323 |


Green cells > current price ($348). Red cells < current price. Base case (8.2% WACC / 2.0% TG) yields $366 — 5.0% above market. At 7.2% WACC (if macro risks recede and patent cliff risk diminishes), the stock looks significantly undervalued ($462-513). At 9.2% (if risks compound), $282-323 — meaningful downside.


| EPS \ P/E              | 11x  | 13x  | 15x  | 17x  | 19x  |
|------------------------|------|------|------|------|------|
| $18 (Trough)           | $198 | $234 | $270 | $306 | $342 |
| $20 (Below Trend)      | $220 | $260 | $300 | $340 | $380 |
| $22 (Consensus)        | $242 | $286 | $330 | $374 | $418 |
| $24 (Bull)             | $264 | $312 | $360 | $408 | $456 |
| $28 (MariTide Success) | $308 | $364 | $420 | $476 | $532 |


Green cells > current price ($348). The "double compression" risk is still real but less acute at $348 vs. $369: the stock now roughly prices $22 EPS at ~16x, which is closer to consensus without premium for MariTide optionality.


## 5. Scenario Analysis & Risk/Reward


### Near-Term Probability Matrix (12-18 Months)


### Long-Term Probability Matrix (3-5 Years)


### Near-Term Risk/Reward at Current Price ($348)


| Scenario       | Target | Prob | Move   | Contribution |
|----------------|--------|------|--------|--------------|
| Bull           | $420   | 20%  | +20.6% | +$14.30      |
| Base           | $355   | 50%  | +1.9%  | +$3.30       |
| Bear           | $275   | 20%  | -21.1% | -$14.70      |
| Severe Bear    | $210   | 10%  | -39.7% | -$13.80      |
| EXPECTED VALUE | $338   | 100% | -3.0%  | -$10.90      |


Expected Upside: +$17.60


Expected Downside: -$28.50


R/R: 0.63:1 (UNFAVORABLE) — Improved from 0.48:1 (Feb report) due to lower entry price. For every $1 of probability-weighted upside, there is $1.59 of downside. The asymmetry has narrowed but remains pronounced because near-term erosion (Prolia/XGEVA/Enbrel) is certain while growth catalysts (MariTide Phase 3, IMDELLTRA first-line) are probabilistic and 9-15 months away.


Expected Value: $338/share (-3.0% price return) — Adding the 2.9% dividend yield gives a total expected return of approximately -0.1%. Essentially break-even on a near-term basis, substantially improved from -1.6% in February.


### Long-Term Risk/Reward (4-Year Horizon)


| Scenario       | LT Target | Prob | Move   | Contribution |
|----------------|-----------|------|--------|--------------|
| Bull           | $540      | 20%  | +55.0% | +$38.30      |
| Base           | $420      | 40%  | +20.6% | +$28.70      |
| Bear           | $280      | 25%  | -19.6% | -$17.10      |
| Severe Bear    | $190      | 15%  | -45.4% | -$23.80      |
| EXPECTED VALUE | $388      | 100% | +11.3% | +$26.10      |


LT Expected Upside: +$67.00


LT Expected Downside: -$40.90


LT R/R: 1.64:1 (NEUTRAL-FAVORABLE) — Improved from 1.34:1 in February. The lower entry price improves long-term asymmetry. Expected price return of +11.3% over 4 years (+2.7% CAGR) improves to ~5.6% total CAGR with the 2.9% annual dividend yield. MariTide Phase 3 success remains the primary upside catalyst.


## 6. Research Agent Findings


| Agent                   | Verdict                         | Key Finding                                                                                                                                                                                                                                                                                              | Sources |
|-------------------------|---------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|
| Competitive Landscape   | CHALLENGING                     | MariTide faces brutal obesity competition: 20% weight loss (ITT 16%) vs. tirzepatide 22-25%, with oral GLP-1s arriving. Enrollment completion is positive signal but doesn't change efficacy math. IMDELLTRA leads SCLC but AbbVie/Merck/Roche investing in next-gen DLL3 agents. 7+ denosumab biosimilars with CVS formulary exclusion now confirmed. | 24 |
| Demand Environment      | MIXED — DETERIORATING           | FY2025 revenue grew 10% to $36.8B but 2026 guidance of 1-4% reveals deceleration. Leerink cut Q1 2026 estimates 4.4% to $8.7B on inventory drawdown. Management expects lower mid-single-digit YoY Q1 decline. Transition pain front-loaded.                                                              | 27 |
| Geopolitical/Regulatory | NET NEGATIVE — ELEVATED         | IRA is structural headwind: Enbrel -67% effective Jan 2026, Otezla IRA Round 2. NEW: Iran war increases biologics supply chain costs ($50-100M annualized). FOMC hawkish hold pressures $54.6B debt refinancing. FDA moving to deem all biosimilars interchangeable.                                        | 31 |
| Product/Moat            | WIDE — STRENGTHENING            | World-class biologics manufacturing (FLEX platform, $2.9B+ investment). BiTE platform producing blockbusters (BLINCYTO $1.5B, IMDELLTRA $627M). Switching costs on specialty products. 14 billion-dollar products. MariTide enrollment complete validates demand signal.                                    | 29 |
| Historical Parallels    | BMY/PFE RISK — LESS ACUTE       | At 15.6x forward P/E (vs. 16.5x in Feb), the stock is cheaper but parallel risk remains. AbbVie bull case requires MariTide visibility BEFORE cliff peak. Enrollment completion is first step but revenue remains zero.                                                                                    | 47 |
| Bear Case               | SUBSTANTIAL                     | Central bear: Prolia -40-50% by 2028, MariTide ITT 14-17%, revenue flat ~$35B, trough EPS ~$20, 12x = $240. Severe bear: MariTide fails + Iran macro shock compounds erosion, 10x on $17 EPS = $170. At 15.6x forward P/E, some cliff discount now embedded.                                             | 35 |
| Bull Case               | COMPELLING — INCREMENTALLY STRONGER | MariTide enrollment complete. MARITIME-CV/HF/OSA broadening label opportunity. Peak sales potential $5-12B+ if cardiovascular outcomes positive. IMDELLTRA underappreciated ($627M to $2-3B). Biosimilar portfolio to $4B+. Repatha+EVENITY at $5B+. Bull FV: $460-540.                                    | 28 |
| Iran War/Macro Overlay  | NET MODEST NEGATIVE              | Healthcare defensive in wartime — AMGN has outperformed since Feb 28. Zero direct ME exposure. But oil-driven biologics logistics costs +$50-100M, FOMC refinancing headwind on $54.6B debt, and risk-off multiple compression partially offset defensive benefit.                                          | 15 |


## 7. Patent Cliff & Pipeline Deep Dive


### The Erosion Math: $9.9B Under Active Decline (Updated)


| Product         | FY2025 Rev | YoY  | 2026 Erosion Forecast | Threat                                           | FY2027E    |
|-----------------|------------|------|-----------------------|--------------------------------------------------|------------|
| Prolia          | $4.4B      | -3%  | -28% (analysts)       | 7 biosimilars, CVS exclusion Apr 2026, 80%+ WAC  | ~$2.2-2.8B |
| XGEVA           | $1.9B      | -6%  | -39% (analysts)       | Same denosumab wave, XGEVA excluded from CVS      | ~$0.8-1.1B |
| Enbrel          | $2.2B      | -33% | -50%+ (IRA pricing)   | IRA -67% pricing, Jan 2026, structural collapse    | ~$0.6-0.8B |
| Otezla          | $1.4B      | -5%  | -10-15% (IRA Rd 2)    | IRA Round 2, IL-17/IL-23 competition               | ~$0.9-1.1B |
| Total Declining | $9.9B      | -12% | -25-35% weighted      | 27% of FY2025 revenue                             | ~$4.5-5.8B |


Combined declining portfolio could lose $4.1-5.4B by FY2027 — approximately 11-15% of current revenue. The erosion forecast has worsened vs. February (was $3.4-4.6B) primarily due to CVS Prolia formulary exclusion and analyst forecasts of accelerated denosumab switching. The key variable is whether physicians resist switching stable Prolia patients despite 80%+ WAC biosimilar discounts and CVS formulary exclusion.


### The Growth Portfolio: $12.4B and Scaling


| Product               | FY2025 Rev | YoY  | TAM                       | Outlook | FY2027E      |
|-----------------------|------------|------|---------------------------|---------|--------------|
| Repatha (PCSK9)       | $3.0B      | +36% | CV/primary prevention     | GROWING | ~$4.5-5.0B   |
| EVENITY (bone)        | $2.1B      | +34% | 60%+ bone builder share   | GROWING | ~$3.0-3.5B   |
| Tezspire (asthma)     | $1.5B      | +52% | Severe asthma + CRSwNP    | GROWING | ~$2.5-3.0B   |
| BLINCYTO (BiTE/ALL)   | $1.5B      | +48% | First-line ALL adoption   | GROWING | ~$2.0-2.5B   |
| IMDELLTRA (BiTE/SCLC) | $0.6B      | New  | SCLC 2L/1L expansion      | RAMPING | ~$1.2-1.8B   |
| Biosimilars           | $3.0B      | +37% | PAVBLU, Wezlana, pipeline | GROWING | ~$3.5-4.0B   |
| UPLIZNA (rare)        | $0.7B      | +73% | NMOSD + IgG4 expansion    | GROWING | ~$1.0-1.2B   |
| Total Growth          | $12.4B     | +37% | —                         | —       | ~$17.7-21.0B |


Growth portfolio should add $5.3-8.6B by FY2027 — the math is tighter now given faster erosion, but still likely to offset most of the declining portfolio's losses. FY2027 trough year now expects roughly -$1-2B net revenue change (slightly worse than the prior neutral estimate).


### Pipeline rNPV: Key Late-Stage Assets (Updated)


| Asset               | Indication                                                      | Phase               | Peak Sales Est.   | PoS        | rNPV ($B) |
|---------------------|-----------------------------------------------------------------|---------------------|-------------------|------------|-----------|
| MariTide            | Obesity (GLP-1/GIP-ant)                                         | Phase 3 (6 studies, 1&2 enrolled) | $5-12B | 55% (up from 50%) | $13.5B |
| Xaluritamig         | Prostate Cancer (BiTE)                                          | Phase 3             | $2-3B             | 35%        | $3B       |
| Tezspire Expansions | EoE, COPD potential                                             | Phase 3             | $2-4B incremental | 50%        | $2B       |
| Biosimilar Pipeline | Pembrolizumab, others                                           | Development         | $2-3B             | 70%        | $3B       |
| AMG 193             | PRMT5i (Oncology)                                               | Phase 2             | $2-4B             | 20%        | $1B       |
| Early Stage         | Aggregate portfolio                                             | Phase 1/Preclinical | Various           | Various    | $2.5B     |
| Total Pipeline rNPV | MariTide is 54% of pipeline value — elevated concentration risk | —                   | —                 | —          | $25B      |


Pipeline rNPV increased $1B to $25B (from $24B): MariTide PoS increase (50% to 55%) on MARITIME-1/2 enrollment completion adds ~$1.5B to rNPV. This is partially offset by slight reduction in early-stage portfolio value. MariTide concentration risk has slightly increased (54% of total, up from 50%).


MariTide Update (March 2026): MARITIME-1 (3,500 patients, obesity without T2D) and MARITIME-2 (999 patients, obesity with T2D) enrollment is COMPLETE. Both studies have readout expected early 2027. Additionally, MARITIME-CV (cardiovascular outcomes in ASCVD patients), MARITIME-HF (heart failure), MARITIME-OSA-1 and MARITIME-OSA-2 (obstructive sleep apnea) are actively enrolling. A new Phase 3 study in T2D is expected to initiate in 2026. The NEJM publication of Phase 2 results provides peer-reviewed validation. Amgen's $2.6B 2026 capex plan includes MariTide manufacturing readiness investment. The breadth of the MARITIME program (8+ studies across 5 indications) would, if successful, position MariTide for a much broader label than obesity alone.


MariTide Competitive Reality Check (Updated): The competitive landscape has intensified. Tirzepatide (Lilly) achieves 22-25% weight loss and now generates $36.5B annually. Semaglutide (Novo) is the established leader. Oral GLP-1 pills are now launched (Novo oral Wegovy approved Dec 2025) with Lilly's oral tirzepatide advancing. MariTide would enter 3-4 years behind incumbents. However, the cardiovascular outcomes program (MARITIME-CV) could be a differentiator if it demonstrates direct MACE reduction in obesity patients — neither Lilly nor Novo has conclusive CV outcomes data from their weight loss formulations. The monthly dosing convenience remains meaningful for patients who prefer fewer injections. ITT weight loss of 16% (vs. 20% completers) remains the key efficacy question for Phase 3.


### SOTP Segment Valuation (Updated)


| Segment                           | Revenue | EV Multiple | Segment EV ($B) | Rationale                                                                     |
|-----------------------------------|---------|-------------|-----------------|-------------------------------------------------------------------------------|
| CV/Bone (Repatha + EVENITY)       | $5.1B   | 11x         | $56B            | Growing 35% combined, patent protection to 2030+                              |
| BiTE Oncology                     | $3.6B   | Mixed       | $36B            | BLINCYTO/IMDELLTRA at 15x ($31.5B) + Kyprolis/Lumakras at 3x ($4.5B)         |
| Rare Disease (Horizon)            | $4.1B   | 8x          | $33B            | TEPEZZA stable, UPLIZNA +73%, rare disease premium                            |
| Biosimilars                       | $3.0B   | 7x          | $21B            | PAVBLU monopoly, pembrolizumab opportunity, +37% growth                       |
| Inflammation (Tez/Tav/Enb/Ote)    | $5.7B   | Mixed       | $18.5B          | Tezspire at 8x + Tavneos at 4x + Enbrel at 0.8x (IRA impaired) + Otezla 1.5x |
| Bone Health Legacy (Prolia/XGEVA) | $6.3B   | 2.5x        | $15.8B          | 7 biosimilars, CVS exclusion confirmed, accelerating erosion (from 3x to 2.5x) |
| Corporate Costs                   | —       | —           | -$12B           | Unallocated SGA, non-product R&D                                              |
| Platform Value                    |         |             | $168.3B         |                                                                               |
| Pipeline rNPV                     |         |             | $25B            | MariTide $13.5B (PoS 55%), xaluritamig $3B, biosimilar pipeline $3B, others $5.5B |
| Platform Premium                  |         |             | $29B            | Capital return $10B + manufacturing $8B + BiTE platform $6B + M&A $5B         |
| Total EV                          |         |             | $222.3B         | - Net Debt $45.5B = Equity $176.8B / 538.5M = $328/share                     |


SOTP adjustments vs. February: Bone Health Legacy reduced from 3x to 2.5x ($19B to $15.8B, -$3.2B) on CVS formulary exclusion confirmation. Inflammation Enbrel reduced from 1x to 0.8x. Pipeline rNPV +$1B (MariTide PoS increase). Net SOTP: $330/share (vs. $333 prior, -$3). The Prolia/XGEVA multiple compression is the primary driver of the SOTP reduction.


## 8. Catalysts


| Catalyst                                              | Timing     | Impact         | Prob | Direction |
|-------------------------------------------------------|------------|----------------|------|-----------|
| MariTide Phase 3 MARITIME-1/2 data readout            | Early 2027 | TRANSFORMATIVE | 55%  | UP        |
| IMDELLTRA first-line SCLC data (DeLLphi-312)          | 2027-2028  | HIGH           | 60%  | UP        |
| Xaluritamig Phase 3 XALute data (mCRPC)               | 2027-2028  | MEDIUM-HIGH    | 35%  | UP        |
| Repatha VESALIUS-CV primary prevention label          | 2026-2027  | MEDIUM         | 75%  | UP        |
| MariTide T2D Phase 3 initiation                       | 2026       | MEDIUM         | 80%  | UP        |
| Prolia/XGEVA erosion trough identification            | Mid-2027   | MEDIUM         | 65%  | UP        |
| Biosimilar pembrolizumab launch                       | 2028-2029  | HIGH           | 65%  | UP        |
| Debt leverage below 2.0x EBITDA                       | 2027-2028  | MEDIUM         | 65%  | UP        |
| Iran ceasefire / oil normalization                    | 2026       | LOW-MEDIUM     | 30%  | UP        |
| MariTide Phase 3 disappoints (ITT <16% or safety)     | Early 2027 | SEVERE         | 25%  | DOWN      |
| Prolia/XGEVA erosion exceeds 40% in 2026             | 2026       | HIGH           | 30%  | DOWN      |
| Tavneos FDA withdrawal proceeds                       | 2026-2027  | MEDIUM         | 35%  | DOWN      |
| Oral GLP-1 pills erode MariTide convenience narrative | 2026-2028  | MEDIUM         | 60%  | DOWN      |
| Additional IRA rounds target Repatha or Prolia        | 2028-2029  | MEDIUM-HIGH    | 45%  | DOWN      |
| Iran war escalation / sustained oil >$120             | 2026       | MEDIUM         | 35%  | DOWN      |
| FOMC no cuts in 2026 / rate increase                  | 2026       | MEDIUM         | 20%  | DOWN      |


## 9. Key Risks


| Risk                                           | Probability  | Impact      | Timeframe  | Mitigant                                                                                                         |
|------------------------------------------------|--------------|-------------|------------|------------------------------------------------------------------------------------------------------------------|
| Prolia/XGEVA accelerated biosimilar erosion    | HIGH         | High        | 2026-2028  | Rebound effect may slow switching; EVENITY captures bone builder share. But CVS exclusion is confirmed headwind  |
| MariTide Phase 3 disappoints                   | Medium (25%) | Severe      | Early 2027 | Diversified growth portfolio provides floor; not all-or-nothing bet. PoS improved to 55% on enrollment           |
| $54.6B debt / higher-for-longer rates          | Medium-High  | Medium-High | Ongoing    | $8.1B FCF enables $5-6B/yr deleveraging; but FOMC hawkish hold makes refinancing more expensive                  |
| IRA expanding to Repatha / Prolia              | Medium (45%) | Medium-High | 2028-2029  | Revenue diversification across 14 products reduces single-drug impact                                            |
| BMY/Pfizer "lost decade" pattern               | Low-Medium   | Severe      | 3-5 years  | Growth portfolio already at $12B+ vs. BMY/PFE which lacked replacement drugs                                     |
| Iran war supply chain disruption               | Medium       | Medium      | 2026       | Zero direct ME exposure. Biologics cold chain inflation ~$50-100M. Healthcare defensive positioning partially offsets |
| GLP-1 second-order TAM compression             | Low          | Medium      | 5-10 years | Novel risk with limited precedent; monitoring required                                                            |


## 10. Macro Overlay: Iran War & FOMC


### Iran War Impact on Amgen (Net Modest Negative)

The US-Iran conflict that began February 28, 2026 affects Amgen through three indirect channels:

**Supply chain inflation (+$50-100M annualized):** Brent crude above $100/barrel increases transportation and cold chain logistics costs for biologics. Amgen ships temperature-sensitive products globally using air freight and refrigerated containers. STAT News reports that pharma supply chains are not yet disrupted but prolonged conflict raises risk of delays, particularly for biologics with short shelf lives.

**Macro uncertainty / risk-off sentiment:** Healthcare is traditionally defensive in wartime. Amgen has zero direct Middle East revenue. The stock has modestly outperformed the S&P 500 since Feb 28 as investors rotated into defensive sectors.

**Interest rate / refinancing pressure:** The Iran war complicates the Fed's inflation outlook. Oil above $100 feeds into transportation and energy costs. The March 18 FOMC hawkish hold (3.50-3.75%, only 1 cut projected) means higher-for-longer. Amgen has ~$8-10B in debt maturing in 2026-2027 that needs refinancing at potentially higher coupons.

**Net assessment:** The defensive benefit (investor rotation into healthcare) roughly offsets the supply chain cost inflation. The primary negative channel is through rates — higher-for-longer increases Amgen's cost of debt and compresses the valuation multiple on a company with $54.6B in leverage. We reflect this in WACC +20bps and EV/EBITDA -0.5x.


### FOMC Impact (Net Negative)

The March 18, 2026 FOMC decision — hold at 3.50-3.75% with only 1 cut projected for 2026 (down from 2 expected) — is net negative for Amgen specifically because:

1. **Debt refinancing:** $54.6B in total debt with ~$8-10B maturing in 2026-2027. Each 25bps higher coupon on refinanced debt adds ~$20-25M to annual interest expense.
2. **Multiple compression:** Higher-for-longer rates compress multiples for levered companies. Pharma median P/E has compressed from ~15.5x to ~15x since January.
3. **Discount rate effect:** Higher risk-free rate flows directly into WACC, reducing present value of future cash flows (particularly MariTide's terminal value contribution).


## 11. Contrarian Checklist

**What Could Make Us Wrong — Bull Direction (more upside than we expect)**

- MariTide Phase 3 delivers 22%+ weight loss with favorable tolerability — monthly dosing becomes preferred in a $100B+ market, adding $5-12B peak revenue
- MARITIME-CV shows direct MACE reduction in obesity patients — unprecedented data that would differentiate MariTide from all competitors
- Iran ceasefire + Fed rate cuts restore risk appetite, compress spreads, benefit levered pharma disproportionately
- IMDELLTRA first-line data is transformative — becomes standard of care across all SCLC, $3-4B franchise
- Prolia rebound effect meaningfully slows biosimilar adoption — CVS formulary exclusion less impactful than feared
- Biosimilar pembrolizumab launches early with strong uptake, adding $2B+ by end of decade

**What Could Make Us Wrong — Bear Direction (more downside than we expect)**

- MariTide enters too late into a market with 5+ competitors including oral pills — monthly injection advantage irrelevant
- Prolia/XGEVA erosion exceeds 40% in 2026 as formulary exclusions cascade beyond CVS
- Iran war escalation (Hormuz closure, oil >$130) triggers recession, compressing all equity multiples 15-20%
- $54.6B debt overhang becomes financial straitjacket if FOMC hikes rates or holds through 2027
- GLP-1 drugs at population scale reduce CV events, cancer incidence, and inflammation TAMs
- BMY post-Celgene pattern materializes: 47% drawdown as growth portfolio fails to match erosion math


## 12. Position Recommendation


### Position Recommendation: HOLD


Rating: FAIRLY PRICED (MID) — Fair Value $344 vs. Current $348 (-1.3%)


Maintain existing weight. Do not add at current levels. Near-term R/R improved to 0.63:1 (from 0.48:1) but still unfavorable due to certain erosion vs. probabilistic growth.


| Accumulate Below | $292 (lower band, -16% from current)        |
|------------------|---------------------------------------------|
| Strong Buy Below | $255 (prices in MariTide failure + erosion) |
| Trim Above       | $396 (upper band)                           |
| Sell Above       | $450 (fully priced growth scenario)         |


Time Horizon: The investment case remains a "2027 story." MariTide Phase 3 readout (early 2027) is the primary inflection point. MARITIME-1/2 enrollment completion provides incremental confidence in the timeline. The Iran war adds a temporary macro overlay that should resolve within 3-6 months in most scenarios, at which point the investment case reverts to the growth-vs-erosion fundamental framework. The 2.9% dividend yield provides modest downside support.


Key Monitoring: (1) MariTide Phase 3 interim/full data, (2) quarterly Prolia/XGEVA erosion pace post-CVS exclusion, (3) IMDELLTRA revenue trajectory, (4) Q1 2026 earnings (April 30) — will reveal actual erosion run rate, (5) Iran war resolution / oil normalization, (6) FOMC June and September meetings for rate guidance, (7) debt leverage ratio trajectory, (8) oral GLP-1 competitive launches.


## 13. Sources & Disclaimer


Data Sources: Amgen SEC filings (10-K, 10-Q, 8-K), Q4 2025 earnings call transcript, FY2026 guidance (Feb 2026), FDA filings (IMDELLTRA full approval, MariTide IND, MARITIME enrollment updates, biosimilar BLAs), ClinicalTrials.gov (MARITIME program, DeLLphi-312, XALute), NEJM (MariTide Phase 2 publication), Bloomberg consensus estimates, FactSet, S&P Capital IQ, sell-side research (JPMorgan, Goldman Sachs, Morgan Stanley, Leerink Partners, BMO Capital, UBS), IQVIA prescription data, CVS Caremark 2026 formulary update, FDA Orange Book patent listings, Moody's credit research, STAT News (pharma supply chain / Iran), FOMC March 18 2026 statement and dot plot, Yahoo Finance, company investor presentations.


Disclaimer: This analysis is generated by inv-AI's valuation framework using Claude Opus 4.6 with 8 specialized research agents (220+ source citations). It is intended for informational and educational purposes only. This is NOT investment advice. All valuations are estimates based on publicly available information and involve significant uncertainty. Past performance does not guarantee future results. The analyst/framework has no position in AMGN. Always conduct your own due diligence and consult with a qualified financial advisor before making investment decisions.


(c) 2026 inv-AI | inv-ai.com | Analysis ID: AMGN-2026-03-24-v2.0 | Prior: AMGN-2026-02-15-v1.0


---

*This report was generated by inv-AI's valuation framework using Claude (Opus 4.6) for analysis and GPT-5.4 for cross-model review. This is NOT financial advice. See [inv-ai.com/terms](https://www.inv-ai.com/terms) for full disclaimer.*

*AI-readable version. For the styled human-readable report, see [AMGN.html](/reports/AMGN.html).*